Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy.
Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ann Surg Oncol. 2021 Mar;28(3):1682-1689. doi: 10.1245/s10434-020-09395-5. Epub 2021 Jan 1.
Desmoid-type fibromatosis represents a challenge in the landscape of surgical oncology, for several reasons. The tumors can be infiltrative and locally aggressive, surgery may be morbid, and patients are usually young, and thus treatment sequelae must be managed for decades. Desmoids do not have metastatic potential, therefore management strategies for desmoids have evolved to employ frontline treatments that are largely non-operative. In fact, with unpredictable and benign behavior, we now recognize that desmoids can also stabilize and regress, making active observation an option for many patients. Moreover, many medical therapies are active in the disease. We reviewed landmark studies describing contemporary issues that affect treatment recommendations for desmoid patients: prognostic factors, indication to active surveillance, role of surgical margins, postoperative radiotherapy, and the most recent expert consensus papers.
纤维瘤病型纤维组织细胞瘤在外科肿瘤学领域是一个挑战,原因有几个。这些肿瘤可能具有浸润性和局部侵袭性,手术可能很复杂,而且患者通常很年轻,因此必须在几十年内处理治疗的后遗症。纤维瘤病型纤维组织细胞瘤没有转移潜能,因此纤维瘤病型纤维组织细胞瘤的治疗策略已经发展为采用主要非手术的一线治疗。事实上,由于其不可预测的良性行为,我们现在认识到纤维瘤病型纤维组织细胞瘤也可以稳定和消退,这使得许多患者可以选择积极观察。此外,许多医学疗法对这种疾病有效。我们回顾了描述影响纤维瘤病型纤维组织细胞瘤患者治疗建议的当代问题的标志性研究:预后因素、主动监测的适应证、手术切缘的作用、术后放疗以及最近的专家共识文件。